Ovarian Cancer section

Ovarian Cancer News & Features

Prevention, Management of Hand-Foot Syndrome With Cooling Therapy

Prevention, Management of Hand-Foot Syndrome With Cooling Therapy

Researchers explored the effectiveness of wearing frozen gloves and socks before and after treatment with PLD to prevent or manage hand-foot syndrome in patients with ovarian cancer.

Normal tissue BRCA1 methylation associated with risk for high-grade ovarian cancer

1. BRCA1 promoter methylation in normal white blood cells (WBCs) was linked to risk for high-grade serous ovarian cancer (HGSOC). 2. BRCA1 methylation was detected in women of all ages, including newborns, suggesting that BRCA1 methylation happens at an embryonic stage. Evidence Rating Level: 3 (Average)     Study Rundown: Females with BRCA1 mutations in their germline []

Pazopanib Plus Paclitaxel Does Not Improve Outcomes in Recurrent Ovarian Cancer

Pazopanib Plus Paclitaxel Does Not Improve Outcomes in Recurrent Ovarian Cancer

Results of a double-blind phase 2 study determined if adding oral pazopanib to intravenous paclitaxel improved outcomes for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Ovarian Cancer Screening Potentially Cost-Effective in the United States

Ovarian Cancer Screening Potentially Cost-Effective in the United States

Multimodal screening is more expensive, but reduces ovarian cancer mortality, researchers found.

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.

Present and Future Roles of PARP Inhibitors in Ovarian Cancer

Present and Future Roles of PARP Inhibitors in Ovarian Cancer

Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.

Niraparib Maintains Quality of Life in Recurrent Ovarian Cancer

Niraparib Maintains Quality of Life in Recurrent Ovarian Cancer

Administering niraparib to patients with recurrent ovarian cancer after CR or PR to platinum-based chemotherapy may allow patients to continuously maintain QOL during treatment, reported researchers in presentation at ESMO 2017 Congress.

Hospital Volume, Quality Impact Survival in Ovarian Cancer

Hospital Volume, Quality Impact Survival in Ovarian Cancer

Survival rate were worse for lower volume hospitals with higher quality scores, versus higher volume hospitals.

Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location

Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location

Risk assessment study for carriers of the BRCA1/2 mutation identified the factors that influence their risk of developing breast cancer, ovarian cancer, or contralateral breast cancer.

Novel Approach Increases Breast, Ovarian Cancer Genetic Screening

Novel Approach Increases Breast, Ovarian Cancer Genetic Screening

A questionnaire added to intake forms at a breast cancer imaging center identified women with BRCA mutations who might otherwise have been missed.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs